Last reviewed · How we verify

NCT07317206

Effects of Single Dose of Ayahuasca or Esketamine on Posttraumatic Stress Disorder: a Randomized, Double-blinded Study

Recruiting now Phase 2 Last updated 19 December 2025
What this trial tests

Phase 2 trial testing Ayahuasca in Posttraumatic Stress Disorder (PTSD) in 10 participants. Currently enrolling.

Timeline
20 December 2025
Primary endpoint
1 June 2026
1 July 2026

Quick facts

Lead sponsorUniversity of Sao Paulo
PhasePhase 2
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment10
Start date20 December 2025
Primary completion1 June 2026
Estimated completion1 July 2026
Sites1 location across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

University of Sao Paulo

Who can join

Adults 18 to 65, any sex, with Posttraumatic Stress Disorder (PTSD). Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

Double-blind, randomized trial comparing a single dose of oral ayahuasca or esketamine in patients with posttraumatic stress disorder.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ayahuasca

Trials testing the same drug.

Other recruiting trials for Posttraumatic Stress Disorder (PTSD)

Currently open trials in the same condition.

Other University of Sao Paulo trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07317206.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing